21-Dec-2009 - US drug major Merck & Co will buy into the UK's contract biologics manufacturing sector with the acquisition of Tees Valley-based Avecia Biologics.
21-Dec-2009 - Hospira will pay India’s Orchid Chemicals and Pharmaceuticals approximately $400m (€278m) for its generic injectables business.
17-Dec-2009 - Swedish CDMO Recipharm will buy privately-owned group Cobra Biomanufacturing to build its presence in the expanding biologics sector.
15-Dec-2009 - Taro Pharmaceutical Industries has warned shareholders about “Sun’s conduct at Caraco” in its latest effort to block the Indian firm’s takeover bid.
15-Dec-2009 - Amcor’s takeover of Alcan has been cleared by the European Commission after the Australian company agreed to sell off two pharmaceutical and food packaging plants in Spain.
11-Dec-2009 - Amcor has unveiled its proposed management shake up in preparation for the $2.025bn takeover of Alcan – three days before the European Commission is due to deliver its verdict on...
07-Dec-2009 - Watson Pharmaceuticals gained US rights to market a generic version of Lipitor (atorvastatin) in 2011 with the acquisition of non-branded drugmaker Arrow Group late last week.
03-Dec-2009 - Australia’s Sterling Products plans to buy a 4,310 sqm pharmaceutical manufacturing plant from a Canadian drugmaker that has fallen victim to the global economic crisis.
26-Nov-2009 - US drugmaker Merck & Co is to close a New Jersey warehouse owned by recent acquisition Schering-Plough, cutting 80 jobs.
24-Nov-2009 - Millipore has acquired the remaining 60 per cent of its Indian joint venture (JV) to drive growth in the country which it views, along with the other BRICS nations, as...
17-Nov-2009 - US biotech Emergent BioSolutions has bought a manufacturing facility from Maryland’s MdBio Foundation is a bid to expand its production infrastructure.
10-Nov-2009 - Pfizer will close six R&D facilities in the US and the UK, reducing its global capacity by over a third following completion of its acquisition of Wyeth.
05-Nov-2009 - US R&D facilities in Rahway and Kenilworth, New Jersey will remain operational as they are vital to the to the newly formed Merck Schering-Plough group, according to CEO Richard Clark....
02-Nov-2009 - Lonza cuts 2009 earning guidance and may reduce its workforce under “Project Bond” cost cutting plan after a Q3 characterized by an “accumulation of unexpected events”
22-Oct-2009 - IMS Health has confirmed it is “exploring strategic alternatives” after speculation this week suggested that the market analysis group had received a number of takeover bids.
20-Oct-2009 - Swiss healthcare services giant Lonza has withdrawn its offer for Canadian CMO Patheon, citing value considerations, rejection of the bid by JLL and the availability of alternatives.
20-Oct-2009 - CNS focused drugmaker H Lundbeck says its acquisition of French CMO Elaiapharm represents a cheaper option than third-party manufacturing.
15-Oct-2009 - US drugmaker Eli Lilly will sell its Tippecanoe laboratories API manufacturing unit to Germany’s Evonik Industries.
15-Oct-2009 - Lonza says that to the Indian market was a key motivation for its acquisition of Simbiosys Biowares India preclinical cell and molecular biology assets.
08-Oct-2009 - We look ahead to CPhI 2009 which takes place in Madrid, Spain next week and will showcase the world’s leading ingredients, contract services, machinery and biotech companies.
07-Oct-2009 - MannKind’s share price tumbled by 31 per cent yesterday, just days after it published encouraging safety data for Afresa, because it revealed a partnership deal is unlikely to occur in 2009.
06-Oct-2009 - Despite the government’s “aggressive” promotion of generic drugs, pharmaceutical spending in France will continue to grow, according to new analysis by Business Monitor International (BMI).
06-Oct-2009 - Hospira has acquired the worldwide rights to filgrastim and a Croatian biologics plant from Pliva, increasing its presence in the biogenerics field, and told in-PharmaTechnologist that further expansions are possible.
01-Oct-2009 - Sun Pharmaceuticals says the new lawsuit filed against it by Taro Pharmaceuticals is “another unfortunate attempt by the Taro directors to divert Taro's limited resources to assisting the Levitt family...
29-Sep-2009 - US health care major J&J has paid €302m for an 18 per cent stake in Dutch biotechnology Crucell and announced plans for a collaborative drug development programme.